Literature DB >> 29762147

Managing Menopause by Combining Evidence With Clinical Judgment.

Chrisandra Shufelt1, Joann Manson2.   

Abstract

In the United States, nearly 10 million women are currently in the menopause transition and 2.25 million women are 51 years of age, which is the average age of menopause. Approximately 75% of these women will experience vasomotor symptoms such as hot flashes and night sweats. Menopause hormone therapy (HT) remains the most effective treatment for menopausal symptoms, but the decision to use HT is complex and requires balancing the benefits and risks for the individual patient. The decision also requires clinical judgment and shared decision making with the patient. In this review, we discuss the current guidelines for HT use, the benefits and risks for the individual patient and a novel algorithm and clinical decision support tool for menopausal symptom management that facilitates shared decision making between clinician and patient.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29762147      PMCID: PMC6059966          DOI: 10.1097/GRF.0000000000000378

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  15 in total

1.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.

Authors:  Rhoda H Cobin; Neil F Goodman
Journal:  Endocr Pract       Date:  2017-07       Impact factor: 3.443

2.  Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society.

Authors:  JoAnn E Manson; Jeffrey M Ames; Marla Shapiro; Margery L S Gass; Jan L Shifren; Cynthia A Stuenkel; JoAnn V Pinkerton; Andrew M Kaunitz; Diane T Pace; Risa Kagan; Peter F Schnatz; Sheryl A Kingsberg; James H Liu; Hadine Joffe; Gloria Richard-Davis; Steven R Goldstein; Isaac Schiff; Wulf H Utian
Journal:  Menopause       Date:  2015-03       Impact factor: 2.953

3.  Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.

Authors:  Christel Renoux; Sophie Dell'aniello; Edeltraut Garbe; Samy Suissa
Journal:  BMJ       Date:  2010-06-03

Review 4.  Hormone replacement therapy and the risk of endometrial cancer: A systematic review.

Authors:  Lea L Sjögren; Lina S Mørch; Ellen Løkkegaard
Journal:  Maturitas       Date:  2016-06-01       Impact factor: 4.342

5.  Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.

Authors:  Susan L Hendrix; Sylvia Wassertheil-Smoller; Karen C Johnson; Barbara V Howard; Charles Kooperberg; Jacques E Rossouw; Maurizio Trevisan; Aaron Aragaki; Alison E Baird; Paul F Bray; Julie E Buring; Michael H Criqui; David Herrington; John K Lynch; Stephen R Rapp; James Torner
Journal:  Circulation       Date:  2006-05-15       Impact factor: 29.690

6.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

7.  Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?

Authors:  Jeanette F Brosnan; Brian L Sheppard; Lucy A Norris
Journal:  Thromb Haemost       Date:  2007-04       Impact factor: 5.249

8.  Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.

Authors:  Cynthia A Stuenkel; Susan R Davis; Anne Gompel; Mary Ann Lumsden; M Hassan Murad; JoAnn V Pinkerton; Richard J Santen
Journal:  J Clin Endocrinol Metab       Date:  2015-10-07       Impact factor: 5.958

9.  Estrogen plus progestin and the risk of coronary heart disease.

Authors:  JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

10.  The 2017 hormone therapy position statement of The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2017-07       Impact factor: 3.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.